Partnerships are a key component of our corporate strategy to maximize the potential of our novel drugs inhibiting various sets of kinases. We offer a portfolio of differentiated and best in class inhibitors along with significant drug discovery and development expertise. Companies interested in collaborating with us are invited to contact us to discuss our portfolio of programs.
Because of our primary focus on developing PI3K inhibitors for treating pediatric cancers we also solicit foundation partnerships and other creative development arrangements with non-profit organizations who also are pushing for new technologies to treat pediatric cancers.
Please submit partnering inquires here.